In Q1 2026, Lifeward reported a 22% revenue decline driven primarily by supply chain constraints affecting AlterG anti-gravity system shipments, partially offset by gains in ReWalk personal exoskeleton sales enabled by expanded payor coverage. Operating losses widened due to a significant one-time IPR&D charge from the Oratech acquisition, reflecting the company's pivot toward integrating new biomedical technologies. Lifeward’s business model centers on advanced robotic exoskeletons primarily for spinal cord injury patients, supplemented by rehabilitation systems acquired via recent strategic transactions. The company faces considerable regulatory complexity and manufacturing challenges amid ongoing cash management efforts but aims to leverage FDA-cleared innovations and expanding distribution partnerships to fuel top-line growth. Watch for developments in reimbursement expansion, clinical trial progress of Oratech assets, and operational execution in scaling AlterG penetration internationally.